30923-92-3

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 46, p. 5413, 1981 DOI: 10.1021/jo00339a035

Upstream product

• 10080-41-8 cyclopentanone hydrazone 
• 646071-31-0 tert-butyl 2-cyclopentylhydrazinecarboxylate 
• 120-92-3 cyclopentanone 
• 79201-39-1 tert-butyl 2-cyclopentylidenehydrazine carboxylate 

Downstream Products

• 38136-09-3 3-(cyclopentylhydrazono-methyl)-rifamycin 
• 92406-52-5 5-amino-1,3-dicyclopentylpyrazole 
• 118431-16-6 methyl 1,3-dicyclopentyl-6-methyl-4-(3-nitrophenyl)-4,7-dihydropyrazolo[3,4-b]pyridine-5-carboxylate 
• 1195779-47-5 13-cyclohexyl-6-[1-cyclopentyl-4-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]carbonyl]-1H-pyrazol-5-yl]-3-methoxy-N-[(1-methylethyl)sulfonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide 
• 1350634-60-4 C₂₅H₃₈N₄O₂ 
• 1350635-29-8 C₂₅H₃₃N₃O₃S 
• 1350633-69-0 C₂₆H₃₃N₃O₃ 
• 1350634-61-5 C₂₆H₃₄N₄O₂ 
• 1608125-61-6 1-cyclopentyl-3-methyl-5-((3-methyl-1-phenyl-1H-pyrazol-5-yl)methoxy)-1H-pyrazole 
• 30241-37-3 1-cyclopentyl-3-methyl-1H-pyrazol-5-amine 
• 3702-09-8 1-cyclopentyl-1H-pyrazol-5-amine 
• 21253-97-4 ethyl 5-amino-1-cyclopentyl-1H-pyrazole-4-carboxylate 
• 30929-67-0 5-amino-1-cyclopentyl-1H-pyrazole-4-carbonitrile 
• 1431140-07-6 C₂₅H₂₈Cl₂N₆O₂ 

Relevant academic research and scientific papers

Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators

The present study describes the discovery and characterization of a series of 5-aryl-2H-tetrazol-3-ylacetamides as G protein-gated inwardly-rectifying potassium (GIRK) channels activators. Working from an initial hit discovered during a high-throughput screening campaign, we identified a tetrazole scaffold that shifts away from the previously reported urea-based scaffolds while remaining effective GIRK1/2 channel activators. In addition, we evaluated the compounds in Tier 1 DMPK assays and have identified a (3-methyl-1H-pyrazol-1-yl)tetrahydrothiophene-1,1-dioxide head group that imparts interesting and unexpected microsomal stability compared to previously-reported pyrazole head groups.

Structure-activity relationships of pyrazole derivatives as potential therapeutics for immune thrombocytopenias

Idiopathic or immune thrombocytopenia (ITP) is a serious clinical disorder involving the destruction of platelets by macrophages. Small molecule therapeutics are highly sought after to ease the burden on current therapies derived from human sources. Earlier, we discovered that dimers of five-membered heterocycles exhibited potential to inhibit phagocytosis of human RBCs by macrophages. Here, we reveal a structure-activity relationship of the bis-pyrazole class of molecules with -C-C-, -C-N- and -C-O- linkers, and their evaluation as inhibitors of phagocytosis of antibody-opsonized human RBCs as potential therapeutics for ITP. We have uncovered three potential candidates, 37, 47 and 50, all carrying a different linker connecting the two pyrazole moieties. Among these compounds, hydroxypyrazole derivative 50 is the most potent compound with an IC50 of 14 ± 9 μM for inhibiting the phagocytosis of antibody-opsonized human RBCs by macrophages. None of the compounds exhibited significant potential to induce apoptosis in peripheral blood mononuclear cells (PBMCs). Current study has revealed specific functional features, such as up to 2-atom spacer arm and alkyl substitution at one of the N1 positions of the bivalent pyrazole core to be important for the inhibitory activity.

Synthesis and Selective Cyclooxygenase-2 Inhibitory Activity of a Series of Novel, Nitric Oxide Donor-Containing Pyrazoles

The synthesis of a series of novel pyrazoles containing a nitrate (ONO 2) moiety as a nitric oxide (NO)-donor functionality is reported. Their COX-1 and COX-2 inhibitory activities in human whole blood are profiled. Our data demonstrate that py

Pyrazol-4-acetic acid compounds

Pyrazol-4-acetic acid compounds, such as substituted pyrazol-4-acetic acid, its esters, amides, nitriles and their pharamaceutically acceptable salts and method for the preparation of these compounds are disclosed. The novel compounds are useful analgesics, anti-inflammatory, and antipyretics.